Sato Vicki L, Vir Biotechnology director, sells $109k in shares

Director Sato Vicki L of Vir Biotechnology (NASDAQ:VIR) sold 22,000 shares of common stock on September 2, 2025, for approximately $109,810. The sales were executed at prices ranging from $4.88 to $5.07, with the stock currently trading at $5.37. The company, valued at $746 million, has seen its shares decline nearly 32% year-to-date.

The transaction was reported in a Form 4 filing with the Securities and Exchange Commission. Following the sale, Sato Vicki L directly owns 1,254,391 shares of Vir Biotechnology. According to InvestingPro analysis, the company is currently burning through cash rapidly and remains unprofitable over the last twelve months.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025. Get access to 8 additional key insights and a comprehensive Pro Research Report for VIR on InvestingPro.

In other recent news, Vir Biotechnology reported its second-quarter earnings for 2025, which showed a deeper-than-expected loss and significant revenue shortfall. The company posted an earnings per share of -0.8 USD, missing the forecast of -0.7 USD, while revenue reached 1.21 million USD, far below the expected 2.66 million USD. This represents a revenue surprise of -54.51%. In addition to the earnings report, Vir Biotechnology has seen notable activity from analysts. Evercore ISI initiated coverage with an Outperform rating and a price target of $12.00, highlighting a "compelling asymmetric setup" for the company. Furthermore, BofA Securities upgraded Vir Biotechnology from Neutral to Buy, raising its price target to $14.00. BofA’s analyst Geoff Meacham emphasized the potential of Vir’s treatment for severe liver disease caused by hepatitis delta virus, projecting over $1 billion in unadjusted peak sales. These developments reflect a mix of challenges and opportunities for Vir Biotechnology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.